CN106831720B — 双-4-(1h-吡唑-1-基)哌啶-1-甲酸叔丁酯的合成方法及其应用
Assigned to Hebei University of Science and Technology · Expires 2019-04-16 · 7y expired
What this patent protects
本发明公开了一种双‑4‑(1H‑吡唑‑1‑基)哌啶‑1‑甲酸叔丁酯的合成方法及双‑4‑(1H‑吡唑‑1‑基)哌啶‑1‑甲酸叔丁酯的应用,它以价廉易得的N‑Boc‑4‑羟基哌啶为原料,经过甲磺酰化反应、烃化反应、格氏反应和Suzuki偶联反应,制得双‑4‑(1H‑吡唑‑1‑基)哌啶‑1‑甲酸叔丁酯,合成方法简单,过程易于控制,所得双‑4‑(1H‑吡唑‑1‑基)哌啶‑1‑甲酸叔丁酯的收率为86.7%;双‑4‑(1H‑吡唑‑1‑基)哌啶‑1‑甲酸叔丁酯可作为标准品,检测和监控克唑替尼的合成。本发明适用于合成双‑4‑(1H‑吡唑‑1‑基)哌啶‑1‑甲酸叔丁酯的合…
USPTO Abstract
本发明公开了一种双‑4‑(1H‑吡唑‑1‑基)哌啶‑1‑甲酸叔丁酯的合成方法及双‑4‑(1H‑吡唑‑1‑基)哌啶‑1‑甲酸叔丁酯的应用,它以价廉易得的N‑Boc‑4‑羟基哌啶为原料,经过甲磺酰化反应、烃化反应、格氏反应和Suzuki偶联反应,制得双‑4‑(1H‑吡唑‑1‑基)哌啶‑1‑甲酸叔丁酯,合成方法简单,过程易于控制,所得双‑4‑(1H‑吡唑‑1‑基)哌啶‑1‑甲酸叔丁酯的收率为86.7%;双‑4‑(1H‑吡唑‑1‑基)哌啶‑1‑甲酸叔丁酯可作为标准品,检测和监控克唑替尼的合成。本发明适用于合成双‑4‑(1H‑吡唑‑1‑基)哌啶‑1‑甲酸叔丁酯的合成,合成物用于检测和监控克唑替尼的合成。
Drugs covered by this patent
- Xalkori (crizotinib) · Pfizer
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.